BRAINSTORM CELL THERAPEUTICS INC.
For the period ended Dec 31, 2025. Filed Mar 31, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 31, 2026
BCLI$0.97+1.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Comprehensive Loss
| | | | | | | |
|---|---|---|---|---|---|---|
| · · Year ended | ||||||
| · · December 31, | ||||||
| · · 2025 · · 2024 | ||||||
| · · U.S. $ in thousands | ||||||
| Operating expenses: · · · · | ||||||
| | | | | | | |
| Research and development | | $4,175 | | $4,651 | ||
| General and administrative | | 5,778 | | 7,042 | ||
| | | | | | | |
| Operating loss | | (9,953) | | (11,693) | ||
| | | | | | | |
| Financial expense, net | | 533 | | 77 | ||
| | | | | | | |
| Gain on change in fair value of Warrants liability (Note 7) | | | 179 | | | 147 |
| | | | | | | |
| Net loss | | $(10,307) | | $(11,623) | ||
| | | | | | | |
| Basic and diluted net loss per share | | $(1.11) | | $(2.31) | ||
| | | | | | | |
| Weighted average number of shares outstanding used in computing basic and diluted net loss per share | | 9,268,976 | | 5,021,798 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.